Perspective: Melanoma diagnosis and monitoring: Sunrise for melanoma therapy but early detection remains in the shade

Melanoma is one of the most dangerous forms of cancer. The five-year survival rate is 98% if it is detected early. However, this rate plummets to 63% for regional disease and 17% when tumors have metastasized, that is, spread to distant sites. Furthermore, the incidence of melanoma has been rising by about 3% per year, whereas the incidence of cancers that are more common is decreasing. A handful of targeted therapies have recently become available that have finally shown real promise for treatment, but for reasons that remain unclear only a fraction of patients respond long term. These drugs often increase survival by only a few months in metastatic patient groups before relapse occurs. More effective treatment may be possible if a diagnosis can be made when the tumor burden is still low. Here, an overview of the current state-of-the-art is provided along with an argument for newer technologies towards early point-of-care diagnosis of melanoma.

💡 Research Summary

Melanoma remains one of the deadliest skin cancers, yet its five‑year survival rate exceeds 98 % when the disease is caught at an early stage. The prognosis deteriorates sharply as the tumor progresses—dropping to 63 % for regional disease and only 17 % once distant metastases appear. Compounding the problem, melanoma incidence is rising at roughly 3 % per year while the incidence of many other common cancers is falling, underscoring an urgent public‑health need for better early detection.

The current diagnostic pathway relies heavily on clinical examination by dermatologists, dermatoscopic imaging, and histopathologic confirmation after a skin biopsy. Dermatoscopy, while valuable, is operator‑dependent and lacks quantitative rigor. High‑resolution, non‑invasive imaging modalities such as reflectance confocal microscopy (RCM) and optical coherence tomography (OCT) provide near‑histologic detail but are limited by cost, training requirements, and limited availability in routine practice. Molecular testing for driver mutations (BRAF, NRAS, KIT) using PCR or next‑generation sequencing (NGS) is increasingly used, and liquid‑biopsy approaches—circulating tumor DNA (ctDNA), microRNA, and exosome profiling—are being explored as minimally invasive screening tools. However, these assays still suffer from suboptimal sensitivity, lack of standardization, and high per‑test expense, preventing widespread adoption for population‑level screening.

Therapeutically, the last decade has seen the introduction of BRAF/MEK inhibitors (e.g., vemurafenib, dabrafenib) and immune checkpoint inhibitors targeting PD‑1 or CTLA‑4 (e.g., pembrolizumab, nivolumab). These agents have extended median overall survival in metastatic melanoma by several months to a few years, yet durable responses are limited to a minority of patients. Resistance mechanisms—including MAPK pathway re‑activation, loss of PTEN, and an immunosuppressive tumor microenvironment—frequently emerge, leading to relapse. Consequently, the authors argue that the most effective way to improve outcomes is to intervene when tumor burden is still low, which requires reliable, rapid, and accessible early‑diagnosis technologies.

The paper outlines a forward‑looking roadmap centered on point‑of‑care (POC) diagnostics, artificial‑intelligence (AI) image analysis, digital pathology, and integrated theranostic platforms.

1. POC Molecular Sensors – Microfluidic and electrochemical devices capable of detecting BRAF V600E/K mutations from minute skin‑surface samples (scraping or microneedle aspirates) in minutes. Nanoparticle‑based colorimetric assays are also discussed as low‑cost, visually interpretable alternatives for field use.

2. AI‑Driven Dermatoscopy – Deep‑learning models trained on large, curated dermatoscopic image repositories can quantify color distribution, asymmetry, border irregularity, and structural patterns, delivering an objective malignancy score. Recent studies show AI performance comparable to or exceeding expert dermatologists, making it suitable for tele‑screening and primary‑care triage.

3. Digital Pathology & Remote Collaboration – Whole‑slide imaging combined with cloud‑based AI pre‑screening enables pathologists to review cases remotely, dramatically shortening the time from biopsy to definitive diagnosis and reducing geographic disparities in expertise.

4. Theranostic Integration – By linking the molecular profile obtained at the point of diagnosis (e.g., BRAF status, immune‑gene signatures) directly to a personalized treatment algorithm, clinicians can initiate targeted therapy or immunotherapy while the disease is still at a low burden. The authors envision “smart clinics” where diagnostic devices, electronic health records, and decision‑support algorithms operate in a seamless loop, facilitating rapid treatment initiation and real‑time monitoring of response.

The authors conclude that existing clinical and molecular tools are insufficient to meet the growing need for early melanoma detection. A multidisciplinary effort—combining advances in biosensor engineering, AI, informatics, and regulatory science—is essential to close the gap. If successfully implemented, these next‑generation technologies could shift melanoma management from a reactive, late‑stage paradigm to a proactive, early‑intervention model, dramatically improving survival and quality of life for patients worldwide.